《新股消息》諾亞控股-S(06686.HK)公開發售超購2.3倍 中籤率100%
中國高淨值財富管理服務提供商諾亞控股-S(06686.HK)公布招股結果,每股發售價定為292元,香港公開發售部分錄得超額認購約2.26倍。每手20股,100%中籤率,該股將於明日(13日)掛牌。獨家保薦人為高盛。
公司上市料淨集資約2.7億元,約35%將用作進一步拓展財富管理業務;約15%將用作進一步拓展資產管理業務;約20%將用作選擇性地進行潛在投資;約10%將用作各業務線的內部科技研發投資;約10%將用作擴展海外業務;及約10%將用作一般企業用途,包括但不限於營運資金及經營開支。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.